Understanding eNOS for pharmacological modulation of endothelial function: A translational view

Current Pharmaceutical Design

Volumn 13, Issue 17, 2007, Pages 1727-1740

  Braam, Branko ^a   Verhaar, Marianne C ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Atherosclerosis; Chronic renal failure; Diabetes mellitus; eNOS uncoupling; Hypercholesterolemia; Nitric oxide

Indexed keywords

ARGININE; ASCORBIC ACID; ATORVASTATIN; CAVEOLIN 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FOLIC ACID; GUANYLATE CYCLASE; INSULIN; MESSENGER RNA; NITRIC OXIDE; OXIPURINOL; PTERIDINE; REACTIVE OXYGEN METABOLITE; UNCOUPLING PROTEIN;

ATHEROSCLEROSIS; BIOLOGICAL ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME PHOSPHORYLATION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY TRANSPLANTATION; MYRISTYLATION; NONHUMAN; PALMITOYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SHEAR STRESS; SIGNAL TRANSDUCTION; SMOKING;

ANIMALS; ATHEROSCLEROSIS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GUANYLATE CYCLASE; HUMANS; KIDNEY DISEASES, CYSTIC; MYRISTIC ACID; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PALMITIC ACID; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; REACTIVE OXYGEN SPECIES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 34250827108     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207780831275     Document Type: Review

References (203)

1. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: Structure, function and inhibition. Biochem J 2001; 357: 593-615.
2. Marsden PA, Schappert KT, Chen HS, Flowers M, Sundell CL, Wilcox JN, et al. Molecular cloning and characterization of human endothelial nitric oxide synthase. FEBS Lett 1992; 307: 287-93.
3. Janssens SP, Shimouchi A, Quertermous T, Bloch DB, Bloch KD. Cloning and expression of a cDNA encoding human endothelium-derived relaxing factor/ nitric oxide synthase. J Biol Chem 1992; 267: 14519-22.
4. Zhang R, Min W, Sessa WC. Functional analysis of the human endothelial nitric oxide synthase promoter. Sp1 and GATA factors are necessary for basal transcription in endothelial cells. J Biol Chem 1995; 270: 15320-6.
5. Lin Z, Kumar A, SenBanerjee S, Staniszewski K, Parmar K, Vaughan DE, et al. Kruppel-like factor 2 (KLF2) regulates endothelial thrombotic function. Circ Res 2005; 96: E48-57.
6. Fleming I, Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol 2003; 284: R1-12.
7. Pollock JS, Klinghofer V, Forstermann U, Murad F. Endothelial nitric oxide synthase is myristylated. FEBS Lett 1992; 309: 402-4.
8. Liu J, Garcia-Cardena G, Sessa WC. Palmitoylation of endothelial nitric oxide synthase is necessary for optimal stimulated release of nitric oxide: Implications for caveolae localization. Biochemistry 1996; 35: 13277-81.
9. Feron O, Saldana F, Michel JB, Michel T. The endothelial nitric-oxide synthase-caveolin regulatory cycle. J Biol Chem 1998; 273: 3125-8.
10. Prabhakar P, Thatte HS, Goetz RM, Cho MR, Golan DE, Michel T. Receptor-regulated translocation of endothelial nitric-oxide synthase. J Biol Chem 1998; 273: 27383-8.
11. Rizzo V, McIntosh DP, Oh P, Schnitzer JE. In situ flow activates endothelial nitric oxide synthase in luminal caveolae of endothelium with rapid caveolin dissociation and calmodulin association. J Biol Chem 1998; 273: 34724-9.
12. Nishida K, Harrison DG, Navas JP, Fisher AA, Dockery SP, Uematsu M, et al. Molecular cloning and characterization of the constitutive bovine aortic endothelial cell nitric oxide synthase. J Clin Invest 1992; 90: 2092-6.
13. Woodman CR, Muller JM, Rush JW, Laughlin MH, Price EM. Flow regulation of ecNOS and Cu/Zn SOD mRNA expression in porcine coronary arterioles. Am J Physiol 1999; 276: H1058-63.
14. Ranjan V, Xiao Z, Diamond SL. Constitutive NOS expression in cultured endothelial cells is elevated by fluid shear stress. Am J Physiol 1995; 269: H550-5.
15. Davis ME, Cai H, Drummond GR, Harrison DG. Shear stress regulates endothelial nitric oxide synthase expression through c-Src by divergent signaling pathways. Circ Res 2001; 89: 1073-80.
16. Malek AM, Jiang L, Lee I, Sessa WC, Izumo S, Alper SL. Induction of nitric oxide synthase mRNA by shear stress requires intracellular calcium and G-protein signals and is modulated by PI 3 kinase. Biochem Biophys Res Commun 1999; 254: 231-42.
17. Davis ME, Grumbach IM, Fukai T, Cutchins A, Harrison DG. Shear stress regulates endothelial nitric-oxide synthase promoter activity through nuclear factor kappaB binding. J Biol Chem 2004; 279: 163-8.
18. Weber M, Hagedorn CH, Harrison DG, Searles CD. Laminar shear stress and 3′ polyadenylation of eNOS mRNA. Circ Res 2005; 96: 1161-8.
19. Malek AM, Izumo S, Alper SL. Modulation by pathophysiological stimuli of the shear stress-induced up-regulation of endothelial nitric oxide synthase expression in endothelial cells. Neurosurgery 1999; 45: 334-44; discussion 344-5.
20. Grumbach IM, Chen W, Mertens SA, Harrison DG. A negative feedback mechanism involving nitric oxide and nuclear factor kappa-B modulates endothelial nitric oxide synthase transcription. J Mol Cell Cardiol 2005; 39: 595-603.
21. Drummond GR, Cai H, Davis ME, Ramasamy S, Harrison DG. Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression by hydrogen peroxide. Circ Res 2000; 86: 347-54.
22. Bouloumie A, Schini-Kerth VB, Busse R. Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells. Cardiovasc Res 1999; 41: 773-80.
23. Govers R, Rabelink TJ. Cellular regulation of endothelial nitric oxide synthase. Am J Physiol Renal Physiol 2001; 280: F193-206.
24. Yoshizumi M, Perrella MA, Burnett JC Jr, Lee ME. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res 1993; 73: 205-9.
25. Shaul PW. Regulation of endothelial nitric oxide synthase: Location, location, location. Annu Rev Physiol 2002; 64: 749-74.
26. Garcia-Cardena G, Oh P, Liu J, Schnitzer JE, Sessa WC. Targeting of nitric oxide synthase to endothelial cell caveolae via palmitoylation: Implications for nitric oxide signaling. Proc Natl Acad Sci USA 1996; 93: 6448-53.
27. Xia Y, Tsai AL, Berka V, Zweier JL. Superoxide generation from endothelial nitric-oxide synthase. A Ca2+/calmodulin-dependent and tetrahydrobiopterin regulatory process. J Biol Chem 1998; 273: 25804-8.
28. Wever RM, van Dam T, van Rijn HJ, de Groot F, Rabelink TJ. Tetrahydrobiopterin regulates superoxide and nitric oxide generation by recombinant endothelial nitric oxide synthase. Biochem Biophys Res Commun 1997; 237: 340-4.
29. Katusic ZS. Vascular endothelial dysfunction: Does tetrahydrobiopterin play a role? Am J Physiol Heart Circ Physiol 2001; 281: H981-6.
30. Stroes E, Hijmering M, van Zandvoort M, Wever R, Rabelink TJ, van Faassen EE. Origin of superoxide production by endothelial nitric oxide synthase. FEBS Lett 1998; 438: 161-4.
31. Hardy TA, May JM. Coordinate regulation of L-arginine uptake and nitric oxide synthase activity in cultured endothelial cells. Free Radic Biol Med 2002; 32: 122-31.
32. Kurz S, Harrison DG. Insulin and the arginine paradox. J Clin Invest 1997; 99: 369-70.
33. Behrendt D, Ganz P. Endothelial function. From vascular biology to clinical applications. Am J Cardiol 2002; 90: 40L-8L.
34. Friebe A, Koesling D. Regulation of nitric oxide-sensitive guanylyl cyclase. Circ Res 2003; 93: 96-105.
35. Yu SM, Hung LM, Lin CC. cGMP-elevating agents suppress proliferation of vascular smooth muscle cells by inhibiting the activation of epidermal growth factor signaling pathway. Circulation 1997; 95: 1269-77.
36. Ichiki T, Usui M, Kato M, Funakoshi Y, Ito K, Egashira K, et al. Downregulation of angiotensin II type 1 receptor gene transcription by nitric oxide. Hypertension 1998; 31: 342-8.
37. Kosonen O, Kankaanranta H, Uotila J, Moilanen E. Inhibition by nitric oxide-releasing compounds of E-selectin expression in and neutrophil adhesion to human endothelial cells. Eur J Pharmacol 2000; 394: 149-56.
38. De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA Jr, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995; 96: 60-8.
39. Bellamy TC, Wood J, Goodwin DA, Garthwaite J. Rapid desensitization of the nitric oxide receptor, soluble guanylyl cyclase, underlies diversity of cellular cGMP responses. Proc Natl Acad Sci USA 2000; 97: 2928-33
40. Ferrero R, Torres M. Prolonged exposure of chromaffin cells to nitric oxide down-regulates the activity of soluble guanylyl cyclase and corresponding mRNA and protein levels. BMC Biochem 2002; 3: 26.
41. Vaziri ND, Wang XQ. cGMP-mediated negative-feedback regulation of endothelial nitric oxide synthase expression by nitric oxide. Hypertension 1999; 34: 1237-41.
42. Lincoln TM, Dey N, Sellak H. Invited review: CGMP-dependent protein kinase signaling mechanisms in smooth muscle: From the regulation of tone to gene expression. J Appl Physiol 2001; 91: 1421-30.
43. Feil R, Lohmann SM, de Jonge H, Walter U, Hofmann F. Cyclic GMP-dependent protein kinases and the cardiovascular system: Insights from genetically modified mice. Circ Res 2003; 93: 907-16.
44. Pilz RB, Casteel DE. Regulation of gene expression by cyclic GMP. Circ Res 2003; 93: 1034-46.
45. Rupprecht HD, Akagi Y, Keil A, Hofer G. Nitric oxide inhibits growth of glomerular mesangial cells: Role of the transcription factor EGR-1. Kidney Int 2000; 57: 70-82.
46. Bogdan C. Nitric oxide and the regulation of gene expression. Trends Cell Biol 2001; 11: 66-75.
47. Ravi K, Brennan LA, Levic S, Ross PA, Black SM. S-nitrosylation of endothelial nitric oxide synthase is associated with monomerization and decreased enzyme activity. Proc Natl Acad Sci USA 2004; 101: 2619-24
48. Braam B, De Roos R, Dijk A, Boer P, Post JA, Kemmeren PP, et al. Nitric Oxide Donor Induces Temporal and Dose-Dependent Reduction of Gene Expression in Human Endothelial Cells. Am J Physiol Heart Circ Physiol 2004; 287: H1977-86.
49. Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C, Technau-Ihling K, et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 2003; 9: 1370-6.
50. Laufs U, Werner N, Link A, Endres M, Wassmann S, Jurgens K, et al. Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation 2004; 109: 220-6.
51. Iwakura A, Luedemann C, Shastry S, Hanley A, Kearney M, Aikawa R, et al. Estrogen-mediated, endothelial nitric oxide synthase-dependent mobilization of bone marrow-derived endothelial progenitor cells contributes to reendothelialization after arterial injury. Circulation 2003; 108: 3115-21.
52. Stroes E, Kastelein J, Cosentino F, Erkelens W, Wever R, Koomans H, et al. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest 1997; 99: 41-6.
53. Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 1993; 88: 2510-6.
54. van Ampting JM, Hijmering ML, Beutler JJ, van Etten RE, Koomans HA, Rabelink TJ, et al. Vascular effects of ACE inhibition independent of the renin-angiotensin system in hypertensive renovascular disease: A randomized, double-blind, crossover trial. Hypertension 2001; 37: 40-5.
55. Kiowski W, Linder L, Stoschitzky K, Pfisterer M, Burckhardt D, Burkart F, et al. Diminished vascular response to inhibition of endothelium-derived nitric oxide and enhanced vasoconstriction to exogenously administered endothelin-1 in clinically healthy smokers. Circulation 1994; 90: 27-34.
56. Morris ST, McMurray JJ, Spiers A, Jardine AG. Impaired endothelial function in isolated human uremic resistance arteries. Kidney Int 2001; 60: 1077-82.
57. Bucci M, Roviezzo F, Brancaleone V, Lin MI, Di Lorenzo A, Cicala C, et al. Diabetic mouse angiopathy is linked to progressive sympathetic receptor deletion coupled to an enhanced caveolin-1 expression. Arterioscler Thromb Vasc Biol, 2004, 24, 721-6.
58. Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 2001; 108: 1341-8.
59. Srinivasan S, Hatley ME, Bolick DT, Palmer LA, Edelstein D, Brownlee M, et al. Hyperglycaemia-induced superoxide production decreases eNOS expression via AP-1 activation in aortic endothelial cells. Diabetologia 2004; 47: 1727-34.
60. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 2001; 88: E14-22.
61. Kobayashi T, Matsumoto T, Ooishi K, Kamata K. Differential expression of alpha2D-adrenoceptor and eNOS in aortas from early and later stages of diabetes in Goto-Kakizaki rats. Am J Physiol Heart Circ Physiol 2004; 287: H135-43.
62. Cosentino F, Hishikawa K, Katusic ZS, Luscher TF. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation 1997; 96: 25-8.
63. Ho FM, Liu SH, Liau CS, Huang PJ, Shiah SG, Lin-Shiau SY. Nitric oxide prevents apoptosis of human endothelial cells from high glucose exposure during early stage. J Cell Biochem 1999; 75: 258-63.
64. Lin LY, Lin CY, Ho FM, Liau CS. Up-regulation of the association between heat shock protein 90 and endothelial nitric oxide synthase prevents high glucose-induced apoptosis in human endothelial cells. J Cell Biochem 2005; 94: 194-201.
65. Noyman I, Marikovsky M, Sasson S, Stark AH, Bernath K, Seger R, et al. Hyperglycemia reduces nitric oxide synthase and glycogen synthase activity in endothelial cells. Nitric Oxide 2002; 7: 187-93.
66. Barua RS, Ambrose JA, Srivastava S, DeVoe MC, Eales-Reynolds LJ. Reactive oxygen species are involved in smoking-induced dysfunction of nitric oxide biosynthesis and upregulation of endothelial nitric oxide synthase: An in vitro demonstration in human coronary artery endothelial cells. Circulation 2003; 107: 2342-7.
67. Li H, Wallerath T, Munzel T, Forstermann U. Regulation of endothelial-type NO synthase expression in pathophysiology and in response to drugs. Nitric Oxide 2002; 7: 149-64.
68. Racasan S, Joles JA, Boer P, Koomans HA, Braam B. NO dependency of RBF and autoregulation in the spontaneously hypertensive rat. Am J Physiol Renal Physiol 2003; 285: F105-12.
69. Schnackenberg CG, Welch WJ, Wilcox CS. Normalization of blood pressure and renal vascular resistance in SHR with a membrane-permeable superoxide dismutase mimetic: Role of nitric oxide. Hypertension 1998; 32: 59-64.
70. Mollnau H, Wendt M, Szocs K, Lassegue B, Schulz E, Oelze M, et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 2002; 90; E58-65.
71. Vaziri ND, Ding Y, Ni Z. Compensatory up-regulation of nitric-oxide synthase isoforms in lead-induced hypertension; reversal by a superoxide dismutase-mimetic drug. J Pharmacol Exp Ther 2001; 298: 679-85.
72. Bouloumie A, Bauersachs J, Linz W, Scholkens BA, Wiemer G, Fleming I, et al. Endothelial dysfunction coincides with an enhanced nitric oxide synthase expression and superoxide anion production. Hypertension 1997; 30: 934-41.
73. Peterson TE, Poppa V, Ueba H, Wu A, Yan C, Berk BC. Opposing effects of reactive oxygen species and cholesterol on endothelial nitric oxide synthase and endothelial cell caveolae. Circ Res 1999; 85: 29-37.
74. Pritchard KA, Ackerman AW, Ou J, Curtis M, Smalley DM, Fontana JT, et al. Native low-density lipoprotein induces endothelial nitric oxide synthase dysfunction: Role of heat shock protein 90 and caveolin-1. Free Radic Biol Med 2002; 33: 52-62.
75. Feron O, Dessy C, Moniotte S, Desager JP, Balligand JL. Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. J Clin Invest 1999; 103: 897-905.
76. Jimenez A, Arriero MM, Lopez-Blaya A, Gonzalez-Fernandez F, Garcia R, Fortes J, et al. Regulation of endothelial nitric oxide synthase expression in the vascular wall and in mononuclear cells from hypercholesterolemic rabbits. Circulation 2001; 104: 1822-30.
77. d'Uscio LV, Smith LA, Katusic ZS. Hypercholesterolemia impairs endothelium-dependent relaxations in common carotid arteries of apolipoprotein e-deficient mice. Stroke 2001; 32: 2658-64.
78. Attia DM, Feron O, Goldschmeding R, Radermakers LH, Vaziri ND, Boer P, et al. Hypercholesterolemia in rats induces podocyte stress and decreases renal cortical nitric oxide synthesis via an angiotensin II type 1 receptor-sensitive mechanism. J Am Soc Nephrol 2004; 15: 949-57.
79. Yeh DC, Duncan JA, Yamashita S, Michel T. Depalmitoylation of endothelial nitric-oxide synthase by acyl-protein thioesterase 1 is potentiated by Ca(2+)-calmodulin. J Biol Chem 1999; 274: 33148-54.
80. Weis MT, Crumley JL, Young LH, Stallone JN. Inhibiting long chain fatty Acyl CoA synthetase increases basal and agoniststimulated NO synthesis in endothelium. Cardiovasc Res 2004; 63: 338-46.
81. Blair A, Shaul PW, Yuhanna IS, Conrad PA, Smart EJ. Oxidized low density lipoprotein displaces endothelial nitric-oxide synthase (eNOS) from plasmalemmal caveolae and impairs eNOS activation. J Biol Chem 1999; 274: 32512-9.
82. Perreault M, Dombrowski L, Marette A. Mechanism of impaired nitric oxide synthase activity in skeletal muscle of streptozotocin-induced diabetic rats. Diabetologia 2000; 43: 427-37.
83. Piech A, Dessy C, Havaux X, Feron O, Balligand JL. Differential regulation of nitric oxide synthases and their allosteric regulators in heart and vessels of hypertensive rats. Cardiovasc Res 2003; 57: 456-67.
84. Sanchez M, Galisteo M, Vera R, Villar IC, Zarzuelo A, Tamargo J, et al. Quercetin downregulates NADPH oxidase, increases eNOS activity and prevents endothelial dysfunction in spontaneously hypertensive rats. J Hypertens 2006; 24: 75-84.
85. Kobayashi N, Mori Y, Nakano S, Tsubokou Y, Kobayashi T, Shirataki H, et al. TCV-116 stimulates eNOS and caveolin-1 expression and improves coronary microvascular remodeling in normotensive and angiotensin II-induced hypertensive rats. Atherosclerosis 2001; 158: 359-68.
86. Feron O, Dessy C, Desager JP, Balligand JL. Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001; 103: 113-8.
87. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999; 399: 597-601.
88. Turkstra E, Braam B, Koomans HA. Impaired renal blood flow autoregulation in two-kidney, one-clip hypertensive rats is caused by enhanced activity of nitric oxide. J Am Soc Nephrol 2000; 11: 847-55
89. Hiyoshi H, Yayama K, Takano M, Okamoto H. Angiotensin type 2 receptor-mediated phosphorylation of eNOS in the aortas of mice with 2-kidney, 1-clip hypertension. Hypertension 2005; 45: 967-73.
90. Hixon ML, Muro-Cacho C, Wagner MW, Obejero-Paz C, Millie E, Fujio Y, et al. Akt1/PKB upregulation leads to vascular smooth muscle cell hypertrophy and polyploidization. J Clin Invest 2000; 106: 1011-20.
91. Kawahara S, Umemoto S, Tanaka M, Umeji K, Matsuda S, Kubo M, et al. Up-regulation of Akt and eNOS induces vascular smooth muscle cell differentiation in hypertension in vivo. J Cardiovasc Pharmacol 2005; 45: 367-74.
92. Iaccarino G, Ciccarelli M, Sorriento D, Cipolletta E, Cerullo V, Iovino GL, et al. AKT participates in endothelial dysfunction in hypertension. Circulation 2004; 109: 2587-93.
93. Kobayashi T, Taguchi K, Yasuhiro T, Matsumoto T, Kamata K. Impairment of PI3-K/Akt pathway underlies attenuated endothelial function in aorta of type 2 diabetic mouse model. Hypertension 2004; 44: 956-62.
94. Kim F, Tysseling KA, Rice J, Pham M, Haji L, Gallis BM, et al. Free fatty acid impairment of nitric oxide production in endothelial cells is mediated by IKKbeta. Arterioscler Thromb Vasc Biol 2005; 25: 989-94.
95. Wever R, Boer P, Hijmering M, Stroes E, Verhaar M, Kastelein J, et al. Nitric oxide production is reduced in patients with chronic renal failure. Arterioscler Thromb Vasc Biol 1999; 19: 1168-72.
96. Wu G, Morris SM, Jr. Arginine metabolism: Nitric oxide and beyond. Biochem J 1998; 336 (Pt 1): 1-17.
97. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, et al. Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction: Its role in hypercholesterolemia. Circulation 1998; 98: 1842-7.
98. Boger RH, Bode-Boger SM, Thiele W, Creutzig A, Alexander K, Frolich JC. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol 1998; 32: 1336-44.
99. Egashira K, Hirooka Y, Kuga T, Mohri M, Takeshita A. Effects of L-arginine supplementation on endothelium-dependent coronary vasodilation in patients with angina pectoris and normal coronary arteriograms. Circulation 1996; 94: 130-4.
100. Hand MF, Haynes WG, Webb DJ. Hemodialysis and L-arginine, but not D-arginine, correct renal failure-associated endothelial dysfunction. Kidney Int 1998; 53: 1068-77.
101. Lekakis JP, Papathanassiou S, Papaioannou TG, Papamichael CM, Zakopoulos N, Kotsis V, et al. Oral L-arginine improves endothelial dysfunction in patients with essential hypertension. Int J Cardiol 2002; 86: 317-23.
102. Rector TS, Bank AJ, Mullen KA, Tschumperlin LK, Sih R, Pillai K, et al. Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure. Circulation 1996; 93: 2135-41.
103. Vos IH, Rabelink TJ, Dorland B, Loos R, Van Middelaar B, Grone HJ, et al. L-arginine supplementation improves function and reduces inflammation in renal allografts. J Am Soc Nephrol 2001; 12: 361-7.
104. Sydow K, Schwedhelm E, Arakawa N, Bode-Boger SM, Tsikas D, Hornig B, et al. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: Effects of Larginine and B vitamins. Cardiovasc Res 2003; 57: 244-52.
105. Dayoub H, Achan V, Adimoolam S, Jacobi J, Stuehlinger MC, Wang BY, et al. Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: Genetic and physiological evidence. Circulation 2003; 108: 3042-7.
106. Tanaka M, Sydow K, Gunawan F, Jacobi J, Tsao PS, Robbins RC, et al. Dimethylarginine dimethylaminohydrolase overexpression suppresses graft coronary artery disease. Circulation 2005; 112: 1549-56.
107. Bevers LM, Braam B, Post JA, van Zonneveld AJ, Rabelink TJ, Koomans HA, et al. Tetrahydrobiopterin, but not L-arginine, decreases NO synthase uncoupling in cells expressing high levels of endothelial NO synthase. Hypertension 2006; 47: 87-94.
108. Chen J, Kuhlencordt P, Urano F, Ichinose H, Astern J, Huang PL. Effects of chronic treatment with L-arginine on atherosclerosis in apoE knockout and apoE/inducible NO synthase double-knockout mice. Arterioscler Thromb Vasc Biol 2003; 23: 97-103.
109. Satoh M, Fujimoto S, Haruna Y, Arakawa S, Horike H, Komai N, et al. NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am J Physiol Renal Physiol 2005; 288: F1144-52.
110. Klahr S, Morrissey J. L-arginine as a therapeutic tool in kidney disease. Semin Nephrol 2004; 24: 389-94.
111. Peters H, Border WA, Ruckert M, Kramer S, Neumayer HH, Noble NA. L-arginine supplementation accelerates renal fibrosis and shortens life span in experimental lupus nephritis. Kidney Int 2003; 63: 1382-92.
112. Heitzer T, Brockhoff C, Mayer B, Warnholtz A, Mollnau H, Henne S, et al. Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers: Evidence for a dysfunctional nitric oxide synthase. Circ Res 2000; 86: E36-41.
113. Cosentino F, Patton S, d'Uscio LV, Werner ER, Werner-Felmayer G, Moreau P, et al. Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats. J Clin Invest 1998; 101: 1530-7.
114. Heitzer T, Krohn K, Albers S, Meinertz T. Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus. Diabetologia 2000; 43: 1435-8.
115. Setoguchi S, Mohri M, Shimokawa H, Takeshita A. Tetrahydrobiopterin improves endothelial dysfunction in coronary microcirculation in patients without epicardial coronary artery disease. J Am Coll Cardiol 2001; 38: 493-8.
116. Meininger CJ, Marinos RS, Hatakeyama K, Martinez-Zaguilan R, Rojas JD, Kelly KA, et al. Impaired nitric oxide production in coronary endothelial cells of the spontaneously diabetic BB rat is due to tetrahydrobiopterin deficiency. Biochem J 2000; 349: 353-6.
117. Shinozaki K, Kashiwagi A, Nishio Y, Okamura T, Yoshida Y, Masada M, et al. Abnormal biopterin metabolism is a major cause of impaired endothelium-dependent relaxation through nitric oxide/O2-imbalance in insulin-resistant rat aorta. Diabetes 1999; 48: 2437-45.
118. Hong HJ, Hsiao G, Cheng TH, Yen MH. Supplemention with tetrahydrobiopterin suppresses the development of hypertension in spontaneously hypertensive rats. Hypertension 2001; 38: 1044-8.
119. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 2003; 111: 1201-9.
120. Vasquez-Vivar J, Duquaine D, Whitsett J, Kalyanaraman B, Rajagopalan S. Altered tetrahydrobiopterin metabolism in atherosclerosis: Implications for use of oxidized tetrahydrobiopterin analogues and thiol antioxidants. Arterioscler Thromb Vasc Biol 2002; 22: 1655-61.
121. Johns DG, Dorrance AM, Tramontini NL, Webb RC. Glucocorticoids inhibit tetrahydrobiopterin-dependent endothelial function. Exp Biol Med (Maywood) 2001; 226: 27-31.
122. Dulak J, Polus M, Guevara I, Hartwich J, Wybranska I, Krzesz R, et al. Oxidized low density lipoprotein inhibits inducible nitric oxide synthase, GTP cyclohydrolase I and transforming growth factor beta gene expression in rat macrophages. J Physiol Pharmacol 1999; 50: 429-41
123. Alp NJ, Channon KM. Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscler Thromb Vasc Biol 2004; 24: 413-20.
124. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993; 91: 2546-51.
125. Lassegue B, Griendling KK. Reactive oxygen species in hypertension; An update. Am J Hypertens 2004; 17: 852-60.
126. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, et al. Mechanisms of increased vascular superoxide production in human diabetes mellitus: Role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 2002; 105: 1656-62.
127. Guzik TJ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R, et al. Vascular superoxide production by NAD(P)H oxidase: Association with endothelial dysfunction and clinical risk factors. Circ Res 2000; 86: E85-90.
128. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996; 97: 1916-23.
129. Warnholtz A, Nickenig G, Schulz E, Macharzina R, Brasen JH, Skatchkov M, et al. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: Evidence for involvement of the renin-angiotensin system. Circulation 1999; 99: 2027-33.
130. Spiekermann S, Landmesser U, Dikalov S, Bredt M, Gamez G, Tatge H, et al. Electron spin resonance characterization of vascular xanthine and NAD(P)H oxidase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation 2003; 107: 1383-9.
131. Cardillo C, Kilcoyne CM, Cannon RO 3rd, Quyyumi AA, Panza JA. Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension 1997; 30: 57-63.
132. Butler R, Morris AD, Belch JJ, Hill A, Struthers AD. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 2000; 35: 746-51.
133. Li M, Absher PM, Liang P, Russell JC, Sobel BE, Fukagawa NK. High glucose concentrations induce oxidative damage to mitochondrial DNA in explanted vascular smooth muscle cells. Exp Biol Med (Maywood) 2001; 226: 450-7.
134. Ballinger SW, Patterson C, Knight-Lozano CA, Burow DL, Conklin CA, Hu Z, et al. Mitochondrial integrity and function in atherogenesis. Circulation 2002; 106: 544-9.
135. Maurice DH, Palmer D, Tilley DG, Dunkerley HA, Netherton SJ, Raymond DR, et al. Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol Pharmacol 2003; 64: 533-46.
136. Mullershausen F, Russwurm M, Thompson WJ, Liu L, Koesling D, Friebe A. Rapid nitric oxide-induced desensitization of the cGMP response is caused by increased activity of phosphodiesterase type 5 paralleled by phosphorylation of the enzyme. J Cell Biol 2001; 155: 271-8.
137. Munzel T, Kurz S, Heitzer T, Harrison DG. New insights into mechanisms underlying nitrate tolerance. Am J Cardiol 1996; 77: 24C-30C.
138. Munzel T, Sayegh H, Freeman BA, Tarpey MM, Harrison DG. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest 1995; 95: 187-94.
139. Kloss S, Bouloumie A, Mulsch A. Aging and chronic hypertension decrease expression of rat aortic soluble guanylyl cyclase. Hypertension 2000; 35: 43-7.
140. Chen L, Daum G, Fischer JW, Hawkins S, Bochaton-Piallat ML, Gabbiani G, et al. Loss of expression of the beta subunit of soluble guanylyl cyclase prevents nitric oxide-mediated inhibition of DNA synthesis in smooth muscle cells of old rats. Circ Res 2000; 86: 520-5.
141. Bauersachs J, Bouloumie A, Mulsch A, Wiemer G, Fleming I, Busse R. Vasodilator dysfunction in aged spontaneously hypertensive rats: Changes in NO synthase III and soluble guanylyl cyclase expression, and in superoxide anion production. Cardiovasc Res 1998; 37: 772-9.
142. Ruetten H, Zabel U, Linz W, Schmidt HH. Downregulation of soluble guanylyl cyclase in young and aging spontaneously hypertensive rats. Circ Res 1999; 85: 534-41.
143. Marques M, Millas I, Jimenez A, Garcia-Colis E, Rodriguez-Feo JA, Velasco S, et al. Alteration of the soluble guanylate cyclase system in the vascular wall of lead-induced hypertension in rats. J Am Soc Nephrol 2001; 12: 2594-600.
144. Jacke K, Witte K, Lemmer B. Mechanisms involved in the blunted nitric oxide-cGMP pathway in hypertensive TGR(mREN2)27 rats. Eur J Pharmacol 2001; 415: 27-30.
145. Munzel T, Daiber A, Ullrich V, Mulsch A. Vascular consequences of endothelial nitric oxide synthase uncoupling for the activity and expression of the soluble guanylyl cyclase and the cGMPdependent protein kinase. Arterioscler Thromb Vasc Biol 2005; 25: 1551-7.
146. McVeigh GE, Brennan GM, Johnston GD, McDermott BJ, McGrath LT, Henry WR, et al. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulindependent) diabetes mellitus. Diabetologia 1992; 35: 771-6.
147. Watts GF, O'Brien SF, Silvester W, Millar JA. Impaired endothelium-dependent and independent dilatation of forearm resistance arteries in men with diet-treated non-insulin-dependent diabetes: Role of dyslipidaemia. Clin Sci (Lond) 1996; 91: 567-73.
148. Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1996; 27: 567-74.
149. Zanetti M, Barazzoni R, Stebel M, Roder E, Biolo G, Baralle FE, et al. Dysregulation of the endothelial nitric oxide synthase-soluble guanylate cyclase pathway is normalized by insulin in the aorta of diabetic rat. Atherosclerosis 2005; 181: 69-73.
150. Pfeifer A, Klatt P, Massberg S, Ny L, Sausbier M, Hirneiss C, et al. Defective smooth muscle regulation in cGMP kinase I-deficient mice. EMBO J 1998; 17: 3045-51.
151. Arnal JF, Battle T, Menard J, Michel JB. The vasodilatory effect of endogenous nitric oxide is a major counter-regulatory mechanism in the spontaneously hypertensive rat. J Hypertens 1993; 11: 945-50.
152. Schwartz IF, Iaina A, Benedict Y, Wollman Y, Chernichovski T, Brasowski E, et al. Augmented arginine uptake, through modulation of cationic amino acid transporter-1, increases GFR in diabetic rats. Kidney Int 2004; 65: 1311-9.
153. Hiragushi K, Wada J, Eguchi J, Matsuoka T, Yasuhara A, Hashimoto I, et al. The role of adrenomedullin and receptors in glomerular hyperfiltration in streptozotocin-induced diabetic rats. Kidney Int 2004; 65: 540-50.
154. Brands MW, Bell TD, Gibson B. Nitric oxide may prevent hypertension early in diabetes by counteracting renal actions of superoxide. Hypertension 2004; 43: 57-63.
155. Santilli F, Cipollone F, Mezzetti A, Chiarelli F. The role of nitric oxide in the development of diabetic angiopathy. Horm Metab Res 2004; 36: 319-35.
156. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-5.
157. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986; 315: 1046-51.
158. Zeiher AM, Drexler H, Saurbier B, Just H. Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J Clin Invest 1993; 92: 652-62.
159. Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002; 106: 653-8.
160. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899-906.
161. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR, Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101: 948-54.
162. Goligorsky MS. Endothelial cell dysfunction and nitric oxide synthase. Kidney Int 2000; 58: 1360-76.
163. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000; 356: 147-52.
164. Kari JA, Donald AE, Vallance DT, Bruckdorfer KR, Leone A, Mullen MJ, et al. Physiology and biochemistry of endothelial function in children with chronic renal failure. Kidney Int 1997; 52: 468-72.
165. Lilien MR, Schroder CH, Koomans HA. Endothelial function in pediatric patients on peritoneal dialysis: The need for data. Perit Dial Int 2005; 25(Suppl 3): S127-9.
166. Passauer J, Bussemaker E, Range U, Plug M, Gross P. Evidence in vivo showing increase of baseline nitric oxide generation and impairment of endothelium-dependent vasodilation in normotensive patients on chronic hemodialysis. J Am Soc Nephrol 2000; 11: 1726-34.
167. Thambyrajah J, Landray MJ, McGlynn FJ, Jones HJ, Wheeler DC, Townend JN. Abnormalities of endothelial function in patients with predialysis renal failure. Heart 2000; 83: 205-9.
168. Schmidt RJ, Baylis C. Total nitric oxide production is low in patients with chronic renal disease. Kidney Int 2000; 58: 1261-6.
169. Lau T, Owen W, Yu YM, Noviski N, Lyons J, Zurakowski D, et al. Arginine, citrulline, and nitric oxide metabolism in end-stage renal disease patients. J Clin Invest 2000; 105: 1217-25.
170. Yokokawa K, Mankus R, Saklayen MG, Kohno M, Yasunari K, Minami M, et al. Increased nitric oxide production in patients with hypotension during hemodialysis. Ann Intern Med 1995; 123: 35-7.
171. Bonomini M, Pandolfi A, Di Pietro N, Sirolli V, Giardinelli A, Consoli A, et al. Adherence of uremic erythrocytes to vascular endothelium decreases endothelial nitric oxide synthase expression. Kidney Int 2005; 67: 1899-906.
172. Sindhu RK, Ehdaie A, Vaziri ND, Roberts CK. Effects of chronic renal failure on caveolin-1, guanylate cyclase and AKT protein expression. Biochim Biophys Acta 2004; 1690: 231-7.
173. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C. Oxidative stress in end-stage renal disease: An emerging threat to patient outcome. Nephrol Dial Transplant 2003; 18: 1272-80.
174. Martin-Mateo MC, Sanchez-Portugal M, Iglesias S, de Paula A, Bustamante J. Oxidative stress in chronic renal failure. Ren Fail 1999; 21: 155-67.
175. Schnackenberg CG. Oxygen radicals in cardiovascular-renal disease. Curr Opin Pharmacol 2002; 2: 121-5.
176. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-5.
177. Yokoyama K, Tajima M, Yoshida H, Nakayama M, Tokutome G, Sakagami H, et al. Plasma pteridine concentrations in patients with chronic renal failure. Nephrol Dial Transplant 2002; 17: 1032-6.
178. Banerjee D, Rodriguez M, Nag M, Adamson JW. Exposure of endothelial cells to recombinant human erythropoietin induces nitric oxide synthase activity. Kidney Int 2000; 57: 1895-904.
179. Beleslin-Cokic BB, Cokic VP, Yu X, Weksler BB, Schechter AN, Noguchi CT. Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood 2004; 104: 2073-80.
180. Kanagy NL, Perrine MF, Cheung DK, Walker BR. Erythropoietin administration in vivo increases vascular nitric oxide synthase expression. J Cardiovasc Pharmacol 2003; 42: 527-33.
181. Wang XQ, Vaziri ND. Erythropoietin depresses nitric oxide synthase expression by human endothelial cells. Hypertension 1999; 33: 894-9.
182. Braam B. Renal endothelial and macula densa NOS: Integrated response to changes in extracellular fluid volume. Am J Physiol 1999; 276: R1551-61.
183. Olson SC, Dowds TA, Pino PA, Barry MT, Burke-Wolin T. ANG II stimulates endothelial nitric oxide synthase expression in bovine pulmonary artery endothelium. Am J Physiol 1997; 273: L315-21.
184. Hennington BS, Zhang H, Miller MT, Granger JP, Reckelhoff JF. Angiotensin II stimulates synthesis of endothelial nitric oxide synthase. Hypertension 1998; 31: 283-8.
185. Moreno C, Lopez A, Llinas MT, Rodriguez F, Lopez-Farre A, Nava E, et al. Changes in NOS activity and protein expression during acute and prolonged ANG II administration. Am J Physiol Regul Integr Comp Physiol 2002; 282: R31-7.
186. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-8.
187. Fukui T, Ishizaka N, Rajagopalan S, Laursen JB, Capers Q 4th, Taylor WR, et al. p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res 1997; 80: 45-51
188. Ozaki M, Kawashima S, Yamashita T, Hirase T, Namiki M, Inoue N, et al. Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apoE-deficient mice. J Clin Invest 2002; 110: 331-40.
189. d'Uscio LV, Milstien S, Richardson D, Smith L, Katusic ZS. Longterm vitamin C treatment increases vascular tetrahydrobiopterin levels and nitric oxide synthase activity. Circ Res 2003; 92: 88-95.
190. Heller R, Unbehaun A, Schellenberg B, Mayer B, Werner-Felmayer G, Werner ER. L-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin. J Biol Chem 2001; 276: 40-7.
191. Stroes ES, van Faassen EE, Yo M, Martasek P, Boer P, Govers R, et al. Folic acid reverts dysfunction of endothelial nitric oxide synthase. Circ Res 2000; 86: 1129-34.
192. Verhaar MC, Wever RM, Kastelein JJ, van Dam T, Koomans HA, Rabelink TJ. 5-methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation 1998; 97: 237-41.
193. Lowe ER, Everett AC, Lee AJ, Lau M, Dunbar AY, Berka V, et al. Time-dependent inhibition and tetrahydrobiopterin depletion of endothelial nitric-oxide synthase caused by cigarettes. Drug Metab Dispos 2005; 33: 131-8.
194. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129-35.
195. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998; 273: 24266-71.
196. Martinez-Gonzalez J, Raposo B, Rodriguez C, Badimon L. 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition prevents endothelial NO synthase downregulation by atherogenic levels of native LDLs: Balance between transcriptional and posttranscriptional regulation. Arterioscler Thromb Vasc Biol 2001; 21: 804-9.
197. Vergnani L, Hatrik S, Ricci F, Passaro A, Manzoli N, Zuliani G, et al. Effect of native and oxidized low-density lipoprotein on endothelial nitric oxide and superoxide production: Key role of Larginine availability. Circulation 2000; 101: 1261-6.
198. Hattori Y, Nakanishi N, Akimoto K, Yoshida M, Kasai K. HMGCoA reductase inhibitor increases GTP cyclohydrolase I mRNA and tetrahydrobiopterin in vascular endothelial cells. Arterioscler Thromb Vasc Biol 2003; 23: 176-82.
199. Rueckschloss U, Galle J, Holtz J, Zerkowski HR, Morawietz H. Induction of NAD(P)H oxidase by oxidized low-density lipoprotein in human endothelial cells: Antioxidative potential of hydroxymethylglutaryl coenzyme A reductase inhibitor therapy. Circulation 2001; 104: 1767-72.
200. Rikitake Y, Kawashima S, Takeshita S, Yamashita T, Azumi H, Yasuhara M, et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001; 154: 87-96.
201. Bivalacqua TJ, Musicki B, Usta MF, Champion HC, Kadowitz PJ, Burnett AL, et al. Endothelial nitric oxide synthase gene therapy for erectile dysfunction. Curr Pharm Des 2005; 11(31): 4059-67.
202. Buemi M, Aloisi C, Fulvio F, Caccamo C, Cavallaro E, Crasci E, et al. Cardiorenal consequences of atherosclerosis and statins therapy: From the past to the future. Curr Pharm Des 2005; 11(30): 3973-84.
203. Gonzalez-Cadavid NF, Rajfer J. The pleiotropic effects of inducible nitric oxide synthase (iNOS) on the physiology and pathology of penile erection. Curr Pharm Des 2005; 11(31): 4041-6.